Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke
JAMA · 18.02.2025 · 333 (7) · 589
DOI: 10.1001/jama.2024.23480 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 18.02.2025. Verfasst von Chang Liu und 52 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Yuzhong District, China. Hauptthemen laut MEDLINE: Endovascular Procedures, Intracranial Hemorrhages, Ischemic Stroke, Thrombectomy. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Importance Persisting or new thrombi in the distal arteries and the microcirculation have been reported to limit the benefits of successful endovascular thrombectomy for patients with acute ischemic stroke. It remains uncertain whether intra-arterial thrombolysis by urokinase following near-complete to complete reperfusion by thrombectomy improves outcomes among patients with ischemic stroke due to large vessel occlusion.
Objective
To assess the efficacy and adverse events of intra-arterial urokinase after near-complete to complete reperfusion by thrombectomy for acute ischemic stroke due to large vessel occlusion. Design, Setting, and Participants This investigator-initiated, randomized, open-label, blinded–end point trial was implemented at 35 hospitals in China, enrolling 535 patients with proximal intracranial large vessel occlusion presenting within 24 hours of time last known well, who achieved near-complete or complete reperfusion by endovascular thrombectomy and did not receive intravenous thrombolysis prior to the procedure. Recruitment took place between November 15, 2022, and March 29, 2024, with final follow-up on July 4, 2024.
Interventions
Eligible patients were randomly assigned to the intra-arterial urokinase group (a single dose of intra-arterial 100 000 IU urokinase injected in the initial target territory; n = 267) or control group (without intra-arterial thrombolysis; n = 267). Main Outcomes and Measures The primary efficacy outcome was the percentage of patients achieving survival without disability (modified Rankin Scale score of 0 or 1) at 90 days. The primary safety outcomes were mortality at 90 days and incidence of symptomatic intracranial hemorrhage within 48 hours.
Results
A total of 535 patients were enrolled (median age, 69 years; 223 [41.8%] female) and 532 (99.6%) completed the trial. The percentage of patients with survival without disability at 90 days was 45.1% (120/266) in the intra-arterial urokinase group and 40.2% (107/266) in the control group (adjusted risk ratio, 1.13 [95% CI, 0.94-1.36]; P = .19). Mortality at 90 days (18.4% vs 17.3%, respectively; adjusted hazard ratio, 1.06 [95% CI, 0.71-1.59]; P = .77) and incidence of symptomatic intracranial hemorrhage (4.1% vs 4.1%, respectively; adjusted risk ratio, 1.05 [95% CI, 0.45-2.44]; P = .91) were not significantly different between groups. Conclusions and Relevance Among patients with acute ischemic stroke due to large vessel occlusion, adjunct intra-arterial urokinase after near-complete to complete reperfusion by endovascular thrombectomy did not significantly increase the likelihood of survival without disability at 90 days. Trial Registration ChiCTR.org.cn Identifier: ChiCTR2200065617
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Yuzhong District, China.
- Department of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
- Department of Neurosurgery, General Hospital of Southern Theatre Command, Guangzhou, China.
- Department of Neurology, Qujing No. 1 Hospital Affiliated Hospital of Kunming Medical University, Qujing, China.
- Department of Neurology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
- Department of Neurology, The First People's Hospital of Xianyang, Xianyang, Shaanxi, China.
Zitieren
APA
Liu, C., Guo, C., Li, F., Yu, N., Huang, J., Peng, Z., Kong, W., Song, J., Liu, X., Fan, S., Yue, C., Chen, B., Zheng, C., Yuan, X., Sheng, J., Wu, Y., Sun, B., Zhao, Z., Zhu, M., …, & POST-UK investigators (2025). Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke. JAMA, 333(7), 589. https://doi.org/10.1001/jama.2024.23480
Vancouver
Liu C, Guo C, Li F, Yu N, Huang J, Peng Z, et al. Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke. JAMA. 2025;333(7):589. doi:10.1001/jama.2024.23480
BibTeX
@article{Liu2025,
author = {Liu, Chang and Guo, Changwei and Li, Fengli and Yu, Nizhen and Huang, Jiacheng and Peng, Zhouzhou and Kong, Weilin and Song, Jiaxing and Liu, Xiang and Fan, Shitao and Yue, Chengsong and Chen, Boyu and Zheng, Chong and Yuan, Xingyun and Sheng, Jian and Wu, Youlin and Sun, Bo and Zhao, Zengqiang and Zhu, Minzhen and Han, Ling and Shi, Qiang and Xia, Zhongbin and Shang, Xianjin and Li, Fengguang and Li, Rongzong and Yue, Feixue and Jiang, Shunfu and Song, Dengwen and Song, Min and Shan, Yuanjun and Ding, Chawen and Yao, Li and Yang, Yong and Chen, Junbin and He, Wencheng and Pan, Feibao and Zhang, Wensheng and Cai, Tieying and Han, Shibo and Li, Wei and Li, Gongbo and Gong, Chen and Huang, Liping and Huang, Cheng and Wang, Duolao and Kaesmacher, Johannes and Nguyen, Thanh N and Nogueira, Raul G and Saver, Jeffrey L and Zi, Wenjie and Chen, Yangmei and Yang, Qingwu and POST-UK investigators, POST-UK investigators},
title = {Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke},
journal = {JAMA},
year = {2025},
volume = {333},
number = {7},
pages = {589},
doi = {10.1001/jama.2024.23480}
}
EUVIMED